13F Holdings
中文EN

GHRS GH Research PLC IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1855129 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-23.9%
TTM EPS YoY-5.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-21.0%
ROA-20.3%
ROIC (approx.)-86.0%
Asset turnover—

Leverage & solvency

Liabilities / assets3.0%
Debt / equity0.00x
Current ratio34.13x
Interest coverage-131.14x

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-2.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$38.77M$35.02M$29.82M$20.48M$8.55M
SG&A expense$21.95M$15.30M$11.40M$10.07M$6.55M
Operating income-$60.72M-$50.31M-$41.22M-$30.55M-$15.10M
Interest expense$463,000$717,000$723,000$123,000$9,000
Pretax income-$48.26M-$38.96M-$35.59M-$22.46M-$9.20M
Income tax$0$0$0$0$0
Net income-$48.26M-$38.96M-$35.59M-$22.46M-$9.20M
EBITDA-$60.38M-$50.00M-$40.91M-$30.51M-$15.08M
EPS (basic)-0.79-0.75-0.68-0.43-0.21
EPS (diluted)-0.79-0.75-0.68-0.43-0.21
Balance sheet
Cash & equivalents$246.25M$100.79M$78.42M$165.96M$276.78M
Current assets$285.98M$154.22M$164.09M$168.54M$279.84M
PP&E, netmay include right-of-use assets (IFRS)$620,000$748,000$1.07M$97,000$82,000
Total assets$288.23M$188.27M$226.30M$254.36M$279.92M
Current liabilities$8.38M$8.95M$6.70M$4.55M$2.75M
Total liabilities$8.53M$9.32M$7.33M$4.55M$2.75M
Shareholders' equity$279.70M$178.95M$218.97M$249.82M$277.18M
Cash flow statement
Operating cash flow-$43.55M-$42.28M-$33.34M-$26.20M-$15.28M
Capital expenditure$121,000$49,000$100,000$67,000$104,000
Free cash flow-$43.67M-$42.33M-$33.44M-$26.27M-$15.39M
Investing cash flow$46.17M$65.14M-$54.10M-$84.69M-$104,000
Financing cash flow$139.65M-$304,000-$204,000$0$286.45M
Depreciation & amortization$335,000$315,000$315,000$47,000$19,000
Stock-based compensation$8.50M$1.17M$2.29M$1.67M$366,000

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.